We have shown that downregulation of TRIM28 expression results profound changes in breast cancer xenografts including: loss of pluripotency and mesenchymal markers, inhibition of stem cell-associated signaling pathways, reduced ability to induce tumor growth and reduced number of cancer stem cells. The gene discussed is TRIM28; the disease is breast carcinoma.